What changed today in Metabolic: 9 trial updates

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

Source file

1. [1]
   New trial registered: GLP1-SARCO (GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

2. [2]
   New trial registered: Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

3. [3]
   New trial registered: OFF-RAMP (Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

4. [4]
   New trial registered: Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and… (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

5. [5]
   New trial registered: Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

6. [6]
   New trial registered: WB-EMS (WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological…) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

7. [7]
   New trial registered: Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

8. [8]
   New trial registered: Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

9. [9]
   New trial registered: PIVOT (Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access) (opens the source in a new tab)

   Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)Oct 4, 2026

10. [10]
    Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4 (opens the source in a new tab)

    News reportingPharmacy TimesOct 5, 2026Industry coverage — headline and link only

11. [11]
    Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide (opens the source in a new tab)

    News reportingDrug TopicsOct 5, 2026Industry coverage — headline and link only

12. [12]
    Balancing Speed of Onset, Durability, and Comorbidities in Psoriasis Therapy (opens the source in a new tab)

    News reportingDermatology TimesOct 5, 2026Industry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.